Cardiff Oncology Inc (FRA:XE7C)
€ 2.975 -0.145 (-4.65%) Market Cap: 142.29 Mil Enterprise Value: 82.00 Mil PE Ratio: 0 PB Ratio: 2.53 GF Score: 50/100

Cardiff Oncology Inc at Jefferies Healthcare Conference Transcript

Jun 08, 2023 / 02:30PM GMT
Release Date Price: €1.51 (-6.44%)
Srishti Kotiyal
Jefferies LLC - Analyst

Good morning, and welcome to the Jefferies Global Healthcare Conference. My name is Srishti Kotiyal with the Jefferies Investment Banking team, and it is my pleasure to introduce Mark Erlander, CEO of Cardiff Oncology.

Mark Erlander
Cardiff Oncology, Inc. - CEO

Well, thank you very much. And I really look forward to talking to you about what we're doing at Cardiff Oncology. And forward looking. So what's going on at Cardiff Oncology? Really, we have a lot of exciting things happening right now. First of all, at Cardiff, we have really the first-in-class PLK1 inhibitor. We have the only PLK inhibitor that has high selectivity. And we've also shown it's very well tolerated. In over 200 patients in several different trials over the last couple of years, we've shown that has a very well-tolerated with really no safety signals.

Also, we're coming off the heels of some very exciting and robust data and our lead program in CRC specifically KRAS-mutated metastatic colorectal cancer. And specifically, we're looking at

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot